EQS-News: ABIVAX / Key word(s): ConferenceAbivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting23.09.2025 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement. Contact:Patrick MalloySVP, Investor RelationsAbivax [email protected]+1 847 987 4878FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company’s expectations for the potential therapeutic benefit of obefazimod, and the Company’s participation at industry conferences. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release.